Evidence map›Paper›PMID 35884830›Full record

ReviewBiomedicines2022

High Doses of Inhaled Nitric Oxide as an Innovative Antimicrobial Strategy for Lung Infections.

Lorenzo Del Sorbo, Vinicius S Michaelsen, Aadil Ali, Aizhou Wang, Rafaela V P Ribeiro, Marcelo Cypel

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lorenzo Del SorboLatner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, 101 College Street | PMCRT, Toronto, ON M5G 1L7, Canada.
Vinicius S MichaelsenLatner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, 101 College Street | PMCRT, Toronto, ON M5G 1L7, Canada.ORCID 0000-0001-9969-6033
Aadil AliLatner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, 101 College Street | PMCRT, Toronto, ON M5G 1L7, Canada.
Aizhou WangLatner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, 101 College Street | PMCRT, Toronto, ON M5G 1L7, Canada.
Rafaela V P RibeiroLatner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, 101 College Street | PMCRT, Toronto, ON M5G 1L7, Canada.ORCID 0000-0002-5627-9157
Marcelo CypelLatner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, 101 College Street | PMCRT, Toronto, ON M5G 1L7, Canada.
University Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the designation of nitric oxide as "Molecule of the Year" in 1992, the scientific and clinical discoveries concerning this biomolecule have been greatly expanding. Currently, therapies enhancing the release of endogenous nitric oxide or the direct delivery of the exogenous compound are recognized as valuable pharmacological treatments in several disorders. In particular, the administration of inhaled nitric oxide is routinely used to treat patients with pulmonary hypertension or refractory hypoxemia. More recently, inhaled nitric oxide has been studied as a promising antimicrobial treatment strategy against a range of pathogens, including resistant bacterial and fungal infections of the respiratory system. Pre-clinical and clinical findings have demonstrated that, at doses greater than 160 ppm, nitric oxide has antimicrobial properties and can be used to kill a broad range of infectious microorganisms. This review focused on the mechanism of action and current evidence from in vitro studies, animal models and human clinical trials of inhaled high-dose nitric oxide as an innovative antimicrobial therapy for lung infections.

Indexed as

antibacterial effectantiviral effectinhaled nitric oxide administrationlung infectionsnitric oxide

Identifiers

PMID35884830
PMCPMC9312466
OpenAlexW4283689606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.